Dinutuximab

Drug Profile

Dinutuximab

Alternative Names: Anti-GD2 monoclonal antibody ch14.18; Ch14.18; ch14.18-UTC; Chimeric anti-GD2 monoclonal antibody; Unituxin

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator National Cancer Institute (USA)
  • Developer National Cancer Institute (USA); St. John of God Foundation; United Therapeutics Corporation
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Cell death stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Neuroblastoma
  • Discontinued Malignant melanoma

Most Recent Events

  • 04 Apr 2017 United Therapeutics plans a phase II/III trial for Small cell lung cancer (Combination therapy, Refractory metastatic disease, Second-line therapy or greater) (NCT03098030)
  • 27 Oct 2015 Launched for Neuroblastoma (Combination therapy, In adolescents, In children, In infants, Second-line therapy or greater) in USA (IV) prior to October 2015 - first global launch
  • 16 Sep 2015 New Approaches to Neuroblastoma Therapy Consortium and United Therapeutics plan the phase I NANT trial for Neuroblastoma (In infants, In adolescents, In children, In adults, Recurrent; Refractory metastatic disease; Combination therapy) in USA (NCT02573896)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top